Disclaimer

The alfapump® system is currently not approved in the United States or Canada. In the United States and Canada, the alfapump® system is currently under clinical investigation (POSEIDON Study) and is being studied in adult patients with refractory or recurrent ascites due to cirrhosis. DSR® therapy is still in development and it should be noted that any statements regarding safety and efficacy arise from ongoing pre-clinical and clinical investigations which have yet to be completed. There is no link between the DSR® therapy and ongoing investigations with the alfapump® system in Europe, the United States or Canada.

Sequana Medical Announces the Appointment of Kirsten Van Bockstaele as Chief Financial Officer

Zurich, SWITZERLAND – July 12, 2018 – Sequana Medical AG (“Sequana Medical”), a commercial stage medical device company focused on the development of innovative treatment solutions for the management of liver disease, heart failure, malignant ascites and other fluid imbalance disorders, announces today the appointment of Kirsten Van Bockstaele as Chief Financial Officer, with immediate effect. Kirsten is a seasoned finance executive with extensive international experience in the healthcare industry.
Kirsten joins Sequana Medical from Fagron (formerly Arseus), an international pharmaceutical compounding company. Within Fagron, she held a number of senior financial roles, most recently as Vice President of Finance, North America. In this role, Kirsten was responsible for creating and overseeing the company’s financial strategy and policy, positioning Fagron’s North American companies for growth. She also played a pivotal role in building out the North American headquarters, supporting the financial integration of acquisitions and assisting in redirecting the company’s strategy.
Kirsten previously served as Chief Financial Officer for Arseus Dental & Medical Solutions, where she was instrumental in the coordination, support and control of financial activities in key European countries. Her previous roles include Financial Controller at Omega Pharma and Audit Manager at PwC. Kirsten has a degree in Financial and Fiscal Sciences from the University of Antwerp, Belgium.
“We are delighted to welcome Kirsten to Sequana Medical. Kirsten brings significant industry experience and a proven track record of building and leading financial functions in the international healthcare sector,” said Ian Crosbie, Chief Executive Officer, Sequana Medical. “Her expertise and insights will be hugely valuable as we continue to strengthen the Company for long-term growth and expand commercialisation of the alfapump® system.”
“I am delighted to join Sequana Medical during this exciting time of growth,” added Kirsten Van Bockstaele, Chief Financial Officer, Sequana Medical. “Sequana Medical is a true innovator in the management of liver disease, heart failure and other fluid imbalance disorders and I look forward to working with Ian and the team in continuing to bring improved treatment options to patients.”

Download the full press release.

Related Posts

PRESS RELEASES

SUBSCRIBE TO OUR PRESS RELEASES